Ad
related to: latest developments in schizophrenia treatment center
Search results
Results from the WOW.Com Content Network
Cobenfy offers new hope for people with schizophrenia, providing an innovative treatment option that could change how this condition is managed, according to Jelena Kunovac, MD, a board-certified ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
Minerva believed that the findings of this second trial supported the claim that the drug was an effective agent for the treatment of negative symptoms in schizophrenia. However, in October 2022, FDA sent Minerva a refusal to file letter pertaining to the New Drug Application for roluperidone for treating negative symptoms in schizophrenia ...
The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [18] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [19]
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
It was through her work that, in the early 2000s, she heard about a radical new approach to schizophrenia that had been developed by researchers in Australia. Tamara was shocked to discover that this program took a very different attitude toward schizophrenia than nearly everyone who had treated her brother.
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
Ad
related to: latest developments in schizophrenia treatment center